Tagged: Gets

Novartis gets lift from $2.1 million gene therapy Zolgensma

Novartis gets lift from $2.1 million gene therapy Zolgensma

Swiss drugmaker Novartis boosted its 2019 forecasts on Tuesday after beating third-quarter expectations, a feat helped by the sales debut of gene therapy Zolgensma, the world’s most expensive one-time treatment. CEO Vas Narasimhan’s bet on...